Assembly Biosciences (ASMB) Return on Capital Employed (2011 - 2026)
Assembly Biosciences (ASMB) posted quarterly Return on Capital Employed of 6.4% for Q1 2026, up 6505.0% year-over-year from 0.1% in Q1 2025, and down 5.69% quarter-over-quarter from 6.06% in Q4 2025.
Assembly Biosciences (ASMB) Return on Capital Employed (2011 - 2026) Analysis & Trends
Assembly Biosciences' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 6.4% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6505.0% year-over-year to 6.4%; the TTM figure through Mar 2026 stood at 6.4% (up 6505.0% YoY), while the FY2025 annual figure was 8.68%, up 4796.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 6.4%, down from 6.06% in the prior quarter.
- The five-year high for Return on Capital Employed was 6.06% in Q4 2025, with the low at 144.45% in Q3 2023.
- The 5-year median for Return on Capital Employed is 77.38% (2022), against an average of 81.25%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed plunged 6905 bps in 2022, then soared 7426 bps in 2024.
- Assembly Biosciences' Return on Capital Employed stood at 98.69% in 2022, then retreated by 19 bps to 117.54% in 2023, then soared by 38 bps to 73.36% in 2024, then soared by 92 bps to 6.06% in 2025, then slipped by 6 bps to 6.4% in 2026.
- Business Quant data shows ASMB's Return on Capital Employed at 6.4% in Q1 2026, 6.06% in Q4 2025, and 40.6% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | -3.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.39% |
| Mar 31, 2026 | -6.40% |
| Dec 31, 2025 | -6.06% |
| Sep 30, 2025 | -40.60% |
| Jun 30, 2025 | -102.15% |
| Mar 31, 2025 | -71.46% |
| Dec 31, 2024 | -73.36% |
| Sep 30, 2024 | -70.19% |
| Jun 30, 2024 | -66.20% |
| Mar 31, 2024 | -62.29% |
| Dec 31, 2023 | -117.54% |
| Sep 30, 2023 | -144.45% |
| Jun 30, 2023 | -126.37% |
| Mar 31, 2023 | -109.73% |
| Dec 31, 2022 | -98.69% |
| Sep 30, 2022 | -114.53% |
| Jun 30, 2022 | -93.75% |
| Mar 31, 2022 | -77.38% |
| Dec 31, 2021 | -65.06% |
| Sep 30, 2021 | -45.48% |